

# Détection automatique de signaux en pharmacovigilance

## Approche statistique fondée sur les comparaisons multiples

Ismail Ahmed

INSERM UMRS Centre de recherche en Epidémiologie et Santé des Populations - Villejuif

16 novembre 2011

## Introduction (1)

### Pharmacovigilance systems

- ▶ aim at early detection of adverse drug reaction of marketed drugs
- ▶ based on spontaneous reports

### The French pharmacovigilance system

- ▶ set up in 1979
- ▶ currently based on 31 pharmacovigilance centres (CRPV)
- ▶ coordinated by the pharmacovigilance unit of the « Agence Française de Sécurité Sanitaire des Produits de Santé » (Afssaps)

## Introduction (2)

### Large quantity of data

- ▶ In France
  - 2000 - 2010 : 370 000 spontaneous reports
  - More than 30 000 reports per year
- ▶ FDA : 2.6 million, WHO : 3.7 million in 2005

### Automatic signal detection methods

- ▶ Statistical associations within the pharmacovigilance database
- ▶ Potential adverse drug reactions

## Introduction (3)

### Existing methods

- ▶ Based on different probability models and decision rules
- ▶ Frequentist methods :
  - Reporting Odds Ratio (ROR, Netherlands)
  - Proportional Reporting Ratio (PRR, UK and EudraVigilance)
- ▶ Bayesian methods :
  - Gamma Poisson Shrinkage (GPS, USA)
  - Bayesian Confidence Propagation Neural Network (BCPNN, WHO)

France does not use any automatic signal detection method yet

## Introduction (4)

### Main limit of the existing methods

- ▶ Detection rules arbitrarily chosen

### Main objective

- ▶ Decision rule derived from a statistical error criteria
- ▶ Accounting for the multiple comparisons
- ▶ False discovery rate (FDR)

# Outline

Description of the current methods

Extension to the multiple comparison setting

Simulation study

Application to the French pharmacovigilance data

Discussion

## Pharmacovigilance data structure and notations

### Large contingency table crossing all the drugs and all the adverse events

- ▶ French database (ATC5-HLT)
  - 672 classes of drugs (D)  $\times$  820 classes of adverse events (AE)
  - 551 040 cells of which 80% are empty

### For a particular couple (AE<sub>*i*</sub>, D<sub>*j*</sub>)

	Drug <i>j</i>	Other Drugs	
Adverse event <i>i</i>	$n_{ij}$	$n_{i\bar{j}}$	$n_{i\cdot}$
Other adverse events	$n_{\bar{i}j}$	$n_{\bar{i}\bar{j}}$	$n_{\bar{i}\cdot}$
	$n_{\cdot j}$	$n_{\cdot \bar{j}}$	$n$

- ▶  $n_{ij}$  : Number of reports involving AE<sub>*i*</sub> and D<sub>*j*</sub>
- ▶  $n_{i\cdot}$  : Marginal count involving AE<sub>*i*</sub>
- ▶  $n_{\cdot j}$  : Marginal count involving D<sub>*j*</sub>
- ▶  $n$  : Total number of AE-D pairs counts

## Reporting Odds Ratio (ROR) van Puijenbroek *et al.* (2002)

### Association measure

- ▶ For the adverse event-drug pair  $(i, j)$

$$\hat{\psi}_{ij} = \frac{n_{ij} n_{i\bar{j}}}{n_{i\bar{j}} n_{i\bar{j}}}$$

### Signal generation

- ▶  $\ln(\hat{\psi}_{ij})$  is assumed to follow a normal distribution with variance :

$$\widehat{\text{var}}\{\ln(\hat{\psi}_{ij})\} = \frac{1}{n_{ij}} + \frac{1}{n_{i\bar{j}}} + \frac{1}{n_{i\bar{j}}} + \frac{1}{n_{i\bar{j}}}$$

- ▶ A signal is generated if

$$\ln(\hat{\psi}_{ij}) - 1.96 \widehat{\text{var}}\{\ln(\hat{\psi}_{ij})\}^{1/2} > 0$$



## Proportional Reporting Ratio (PRR) Evans *et al.* (2001)

### Association measure

- ▶ For the adverse event-drug pair  $(i, j)$

$$\hat{\varphi}_{ij} = \frac{n_{ij}/n_{i.}}{n_{.j}/n_{.}}$$

- ▶ very close to  $\hat{\psi}_{ij}$

### Signal generation

- ▶ Evans *et al.* (2001)
  - $\hat{\varphi}_{ij} > 2$
  - $n_{ij} \geq 3$
  - A  $\chi^2$  statistic with 1 df  $\geq 4$
- ▶ van Puijenbroek *et al.* (2002) : same as for the ROR method

## Gamma Poisson Shrinkage (GPS) DuMouchel (1999)

### Poisson - 2 gamma mixture model

▶  $n_{ij} | e_{ij}, \lambda_{ij} \sim \mathbf{Pn}(\lambda_{ij} e_{ij})$  avec  $e_{ij} = \frac{n_{i.} n_{.j}}{n}$

▶  $\lambda_{ij} \sim \hat{w} \mathbf{Ga}(\hat{\alpha}_1, \hat{\beta}_1) + (1 - \hat{w}) \mathbf{Ga}(\hat{\alpha}_2, \hat{\beta}_2)$

where  $(\hat{w}, \hat{\alpha}_1, \hat{\alpha}_2, \hat{\beta}_1, \hat{\beta}_2)$  maximizes the marginal likelihood

$$\prod_{ij} [w f_{\mathbf{Bn}}\{n_{ij}; \alpha_1, \beta_1 / (\beta_1 + e_{ij})\} + (1 - w) f_{\mathbf{Bn}}\{n_{ij}; \alpha_2, \beta_2 / (\beta_2 + e_{ij})\}]$$

### Association measure

$$\lambda_{ij}^* = \lambda_{ij} | n_{ij}, e_{ij}$$

▶  $\lambda_{ij}^* \sim w_{ij} \mathbf{Ga}(\hat{\alpha}_1 + n_{ij}, \hat{\beta}_1 + e_{ij}) + (1 - w_{ij}) \mathbf{Ga}(\hat{\alpha}_2 + n_{ij}, \hat{\beta}_2 + e_{ij})$

## Gamma Poisson Shrinkage (GPS) DuMouchel (1999)

### Poisson - 2 gamma mixture model

▶  $n_{ij} | e_{ij}, \lambda_{ij} \sim \mathbf{Pn}(\lambda_{ij} e_{ij})$  avec  $e_{ij} = \frac{n_{i.} \cdot n_{.j}}{n}$

▶  $\lambda_{ij} \sim \hat{w} \mathbf{Ga}(\hat{\alpha}_1, \hat{\beta}_1) + (1 - \hat{w}) \mathbf{Ga}(\hat{\alpha}_2, \hat{\beta}_2)$

where  $(\hat{w}, \hat{\alpha}_1, \hat{\alpha}_2, \hat{\beta}_1, \hat{\beta}_2)$  maximizes the marginal likelihood

$$\prod_{ij} [w f_{\mathbf{Bn}}\{n_{ij}; \alpha_1, \beta_1 / (\beta_1 + e_{ij})\} + (1 - w) f_{\mathbf{Bn}}\{n_{ij}; \alpha_2, \beta_2 / (\beta_2 + e_{ij})\}]$$

### Association measure

$$\lambda_{ij}^* = \lambda_{ij} | n_{ij}, e_{ij}$$

▶  $\lambda_{ij}^* \sim w_{ij} \mathbf{Ga}(\hat{\alpha}_1 + n_{ij}, \hat{\beta}_1 + e_{ij}) + (1 - w_{ij}) \mathbf{Ga}(\hat{\alpha}_2 + n_{ij}, \hat{\beta}_2 + e_{ij})$

### Signal generation

▶  $E\{\log_2(\lambda_{ij}^*)\}$

DuMouchel (1999)

## Gamma Poisson Shrinkage (GPS) DuMouchel (1999)

### Poisson - 2 gamma mixture model

$$\blacktriangleright n_{ij} | e_{ij}, \lambda_{ij} \sim \mathbf{Pn}(\lambda_{ij} e_{ij}) \quad \text{avec} \quad e_{ij} = \frac{n_{i.} \cdot n_{.j}}{n}$$

$$\blacktriangleright \lambda_{ij} \sim \hat{w} \mathbf{Ga}(\hat{\alpha}_1, \hat{\beta}_1) + (1 - \hat{w}) \mathbf{Ga}(\hat{\alpha}_2, \hat{\beta}_2)$$

where  $(\hat{w}, \hat{\alpha}_1, \hat{\alpha}_2, \hat{\beta}_1, \hat{\beta}_2)$  maximizes the marginal likelihood

$$\prod_{ij} [w f_{\mathbf{Bn}}\{n_{ij}; \alpha_1, \beta_1 / (\beta_1 + e_{ij})\} + (1 - w) f_{\mathbf{Bn}}\{n_{ij}; \alpha_2, \beta_2 / (\beta_2 + e_{ij})\}]$$

### Association measure

$$\lambda_{ij}^* = \lambda_{ij} | n_{ij}, e_{ij}$$

$$\blacktriangleright \lambda_{ij}^* \sim w_{ij} \mathbf{Ga}(\hat{\alpha}_1 + n_{ij}, \hat{\beta}_1 + e_{ij}) + (1 - w_{ij}) \mathbf{Ga}(\hat{\alpha}_2 + n_{ij}, \hat{\beta}_2 + e_{ij})$$

### Signal generation

$$\blacktriangleright E\{\log_2(\lambda_{ij}^*)\}$$

DuMouchel (1999)

$$\blacktriangleright Q_{0.05}(\lambda_{ij}^*)$$

DuMouchel *et al.* (2001)

## Gamma Poisson Shrinkage (GPS) DuMouchel (1999)

### Poisson - 2 gamma mixture model

$$\blacktriangleright n_{ij} | e_{ij}, \lambda_{ij} \sim \mathbf{Pn}(\lambda_{ij} e_{ij}) \quad \text{avec} \quad e_{ij} = \frac{n_{i.} \cdot n_{.j}}{n}$$

$$\blacktriangleright \lambda_{ij} \sim \hat{w} \mathbf{Ga}(\hat{\alpha}_1, \hat{\beta}_1) + (1 - \hat{w}) \mathbf{Ga}(\hat{\alpha}_2, \hat{\beta}_2)$$

where  $(\hat{w}, \hat{\alpha}_1, \hat{\alpha}_2, \hat{\beta}_1, \hat{\beta}_2)$  maximizes the marginal likelihood

$$\prod_{ij} [w f_{\mathbf{Bn}}\{n_{ij}; \alpha_1, \beta_1 / (\beta_1 + e_{ij})\} + (1 - w) f_{\mathbf{Bn}}\{n_{ij}; \alpha_2, \beta_2 / (\beta_2 + e_{ij})\}]$$

### Association measure

$$\lambda_{ij}^* = \lambda_{ij} | n_{ij}, e_{ij}$$

$$\blacktriangleright \lambda_{ij}^* \sim w_{ij} \mathbf{Ga}(\hat{\alpha}_1 + n_{ij}, \hat{\beta}_1 + e_{ij}) + (1 - w_{ij}) \mathbf{Ga}(\hat{\alpha}_2 + n_{ij}, \hat{\beta}_2 + e_{ij})$$

### Signal generation

$$\blacktriangleright E\{\log_2(\lambda_{ij}^*)\}$$

DuMouchel (1999)

$$\blacktriangleright Q_{0.05}(\lambda_{ij}^*)$$

DuMouchel *et al.* (2001)

$$\blacktriangleright Q_{0.05}(\lambda_{ij}^*) > 2$$

Szarfman *et al.* (2002)

# Bayesian Confidence Propagation Neural Network (BCPNN) (1)

Bate *et al.* (1998), Noren *et al.* (2006)

## Multinomial-Dirichlet model

$$\begin{aligned} (n_{ij}, n_{i\bar{j}}, n_{\bar{i}j}, n_{\bar{i}\bar{j}}) &\sim \mathbf{Mu}(n, p_{ij}, p_{i\bar{j}}, p_{\bar{i}j}, p_{\bar{i}\bar{j}}) \\ \text{with } (p_{ij}, p_{i\bar{j}}, p_{\bar{i}j}, p_{\bar{i}\bar{j}}) &\sim \mathbf{Di}(\alpha_{ij}, \alpha_{i\bar{j}}, \alpha_{\bar{i}j}, \alpha_{\bar{i}\bar{j}}) \end{aligned}$$

- ▶ The hyperparameters depend on the cell counts
- ▶ The posterior distribution of  $(p_{ij}, p_{i\bar{j}}, p_{\bar{i}j}, p_{\bar{i}\bar{j}})$  is also a Dirichlet :

$$(p_{ij}, p_{i\bar{j}}, p_{\bar{i}j}, p_{\bar{i}\bar{j}})^* \sim \mathbf{Di}(\gamma_{ij}, \gamma_{i\bar{j}}, \gamma_{\bar{i}j}, \gamma_{\bar{i}\bar{j}})$$

with  $\gamma_{kl} = \alpha_{kl} + n_{kl}$

# Bayesian Confidence Propagation Neural Network (BCPNN) (1)

Bate *et al.* (1998), Noren *et al.* (2006)

## Multinomial-Dirichlet model

$$\begin{aligned} (n_{ij}, n_{i\bar{j}}, n_{\bar{i}j}, n_{\bar{i}\bar{j}}) &\sim \mathbf{Mu}(n, p_{ij}, p_{i\bar{j}}, p_{\bar{i}j}, p_{\bar{i}\bar{j}}) \\ \text{with } (p_{ij}, p_{i\bar{j}}, p_{\bar{i}j}, p_{\bar{i}\bar{j}}) &\sim \mathbf{Di}(\alpha_{ij}, \alpha_{i\bar{j}}, \alpha_{\bar{i}j}, \alpha_{\bar{i}\bar{j}}) \end{aligned}$$

- ▶ The hyperparameters depend on the cell counts
- ▶ The posterior distribution of  $(p_{ij}, p_{i\bar{j}}, p_{\bar{i}j}, p_{\bar{i}\bar{j}})$  is also a Dirichlet :

$$(p_{ij}, p_{i\bar{j}}, p_{\bar{i}j}, p_{\bar{i}\bar{j}})^* \sim \mathbf{Di}(\gamma_{ij}, \gamma_{i\bar{j}}, \gamma_{\bar{i}j}, \gamma_{\bar{i}\bar{j}})$$

with  $\gamma_{kl} = \alpha_{kl} + n_{kl}$

- ▶ In particular

$$\begin{aligned} p_{ij}^* &\sim \mathbf{Be}(\gamma_{ij}, \gamma_{i\bar{j}} + \gamma_{\bar{i}j} + \gamma_{\bar{i}\bar{j}}) \\ p_{i\cdot}^* = p_{ij}^* + p_{i\bar{j}}^* &\sim \mathbf{Be}(\gamma_{ij} + \gamma_{i\bar{j}}, \gamma_{\bar{i}j} + \gamma_{\bar{i}\bar{j}}) \\ p_{\cdot j}^* = p_{ij}^* + p_{\bar{i}j}^* &\sim \mathbf{Be}(\gamma_{ij} + \gamma_{\bar{i}j}, \gamma_{i\bar{j}} + \gamma_{\bar{i}\bar{j}}) \end{aligned}$$

## Bayesian Confidence Propagation Neural Network (BCPNN) (2)

Bate *et al.* (1998), Noren *et al.* (2006)

### Association measure

$$IC_{ij}^* = \log_2 \left( \frac{p_{ij}^*}{p_{i.}^* p_{.j}^*} \right)$$

Ratio of beta distributions  $\Rightarrow$  No analytic form

### Signal generation

$$Q_{0.025}(IC_{ij}^*) > 0$$

- ▶ Normal approximation
  - delta method : Bate *et al.* (1998)
  - exact moments : Gould (2003)
- ▶ Interpolation model built from Monte Carlo simulations : Noren *et al.* (2006)



Description of the current methods

**Extension to the multiple comparison setting**

Simulation study

Application to the French pharmacovigilance data

Discussion

## False Discovery Rate and Pharmacovigilance

- ▶ Automatic signal detection methods are data mining tools
- ▶ Extension to the hypothesis testing framework
  - relying on the recent developments in multiple comparison statistical field
  - detection thresholds rule based on statistical criteria
- ▶ False Discovery Rate (Benjamini and Hochberg (1995))
  - E(proportion of false discoveries among the generated signals)
  - used in the genomic data analysis
  - adapted to massive comparisons and exploratory analysis

## Frequentist methods : Proposed approach (1)

### Use of the P-values as statistic of interest

#### ROR

- ▶ For each cell, we want to test  $H_{0_{ij}} : \psi_{ij} \leq \psi_0$
- ▶ The corresponding P-values

$$p_{ij} = 1 - \Phi\left(\frac{\ln(\hat{\psi}_{ij}) - \ln(\psi_0)}{\text{var}[\ln(\hat{\psi}_{ij})]^{1/2}}\right)$$

where  $\Phi$  denotes the standard normal cdf

- ▶ The current decision rule corresponds to
  - choose  $\psi_0 = 1$  and
  - generate signals for cells with  $p_{ij} \leq 0.025$

#### PRR

- ▶  $H_{0_{ij}} : \varphi_{ij} \leq \varphi_0$

## Frequentist methods : Proposed approach (2)

### Fisher's exact test

- ▶ Simple and exact alternative to ROR and PRR
- ▶ Large proportion of cells with small counts
- ▶ P-values :  $\Pr(N_{ij} \geq n_{ij} | n_{i.}, n_{.j}, n; \psi_0)$
- ▶ The Fisher's exact test is known to be conservative
- ▶ mid-P-values :  $\underbrace{\Pr(N_{ij} \geq n_{ij} | n_{i.}, n_{.j}, n; \psi_0)}_{\text{P-values}} - \frac{1}{2} \Pr(N_{ij} = n_{ij} | n_{i.}, n_{.j}, n; \psi_0)$

## Frequentist methods : Proposed approach (3)

### Marginal distribution of the P-values

P-values are assumed to follow a mixture of two distributions

$$f(p) = \pi_0 f_0(p) + (1 - \pi_0) f_1(p)$$

- ▶  $f_0(p)$  is the pdf of  $p$  under the null hypothesis
- ▶  $f_1(p)$  is the pdf of  $p$  under the alternative hypothesis

### FDR Storey *et al.* (2002)

For a P-value rejection region  $[0, \gamma]$  with  $\gamma \in ]0, 1]$

$$\text{FDR}(\gamma) = \frac{\pi_0 F_0(\gamma)}{F(\gamma)}$$

## Frequentist methods : Proposed approach (4)

### FDR estimation : Single null hypothesis (not our case)

- ▶ The P-values are uniformly distributed under the null hypothesis

$$\begin{aligned}f(p) &= \pi_0 f_0(p) + (1 - \pi_0) f_1(p) \\ &= \pi_0 + (1 - \pi_0) f_1(p)\end{aligned}$$

- ▶ For a P-value rejection region  $[0, \gamma]$  with  $\gamma \in ]0, 1]$

$$\text{FDR}(\gamma) = \frac{\pi_0 F_0(\gamma)}{F(\gamma)} = \frac{\pi_0 \gamma}{F(\gamma)}$$

- ▶  $F$  is estimated by its empirical estimate :  $\hat{F}(\gamma) = 1/m \sum_{ij} 1(p_{ij} \leq \gamma)$
- ▶ The main difficulty is to estimate  $\pi_0$

## Frequentist methods : Proposed approach (5)

### Location Based Estimator (LBE) Dalmasso *et al.* 2005

$$E[\varphi(P)] = \pi_0 E_0[\varphi(P)] + (1 - \pi_0) E_1[\varphi(P)]$$

$$\frac{E[\varphi(P)]}{E_0[\varphi(P)]} = \pi_0 + \underbrace{(1 - \pi_0) \frac{E_1[\varphi(P)]}{E_0[\varphi(P)]}}_{\text{non negative term : Bias}}$$

- ▶  $\varphi$  is chosen to minimize the non negative term :  $\varphi(p) = -\ln(1 - p)^a$


$$\hat{\pi}_0 = \frac{\hat{E}[\varphi(P)]}{E_0[\varphi(P)]} = \frac{1/m \sum_{ij} \varphi(p_{ij})}{E_0[\varphi(P)]} = \frac{1/m \sum_{ij} \{-\ln(1 - p_{ij})\}^a}{\Gamma(a + 1)}$$

- ▶ LBE only assumes that  $f$  is a non increasing function
- ▶  $\hat{\pi}_0$  is a biased estimator  $\Rightarrow$  upper bound for the FDR estimation

## Frequentist methods : Proposed approach (6)

### FDR estimation : One-sided null hypothesis

- ▶ The P-values are not calculated under  $H_{0_{ij}} : \psi_{ij} \leq \psi_0$  but under  $H_{0_{ij*}} : \psi_{ij} = \psi_0$
- ▶ The P-values are **not** uniformly distributed under  $H_{0_{ij}}$
- ▶  $f_0$  expressed as a mixture of a uniform  $f_{0*}$  and a non-decreasing  $f_{1*}$  function



$$\begin{aligned}
 f(p) &= \pi_0 + (1 - \pi_0) f_1(p) \\
 &= \pi_0 \{ \pi_{0*} + (1 - \pi_{0*}) f_{1*}(p) \} + (1 - \pi_0) f_1(p)
 \end{aligned}$$

- ▶ In practice, only small values of  $\gamma$  are of interest :

$$\text{FDR}(\gamma) = \frac{\pi_0 F_0(\gamma)}{F(\gamma)} = \frac{\pi_0 \{ \pi_{0*} \gamma + (1 - \pi_{0*}) F_{1*}(\gamma) \}}{F(\gamma)} = \frac{\pi_0 \pi_{0*} \gamma}{F(\gamma)}$$

- ▶ The issue is thus to estimate  $\pi_0 \pi_{0*}$
- ▶ LBE on  $P^* = 1 - 2|P - \frac{1}{2}|$  which has a non-increasing pdf expressed as  $f_{P^*}(p^*) = \pi_0 \pi_{0*} + (1 - \pi_0 \pi_{0*}) f_{1P^*}(p^*)$



## Bayesian methods : Proposed approach (1)

Based on the bayesian decision theory framework - Müller et al. (2004)

Status

$$z_{ij} \in \{0, 1\}$$

Decision

$$d_{ij} \in \{0, 1\}$$

FDR

$$\text{FDP} = \frac{\sum_{ij} (1 - z_{ij}) d_{ij}}{\sum_{ij} d_{ij}} \longrightarrow \text{FDR} = \text{E}[\text{FDP}]$$

Bayesian FDR estimation : FDR\*

$$\text{FDR}^* = \text{E}[\text{FDP} | \text{data}] = \frac{\sum_{ij} u_{ij} d_{ij}}{\sum_{ij} d_{ij}}$$

where  $u_{ij} = \text{Pr}(z_{ij} = 0 | \text{data})$  i.e. the posterior Pr. of  $H_{0ij} : z_{ij} = 0$

## Bayesian methods : Proposed approach (2)

Status  $z_{ij} - u_{ij}$

► For each cell, we want to test

- GPS  $\rightarrow H_{0_{ij}} : \lambda_{ij} \leq RR_0$

- BCPNN  $\rightarrow H_{0_{ij}} : \frac{p_{ij}}{p_{i.} p_{.j}} \leq RR_0$

► and thus to calculate  $u_{ij}$  i.e. the posterior probability of  $H_{0_{ij}}$

- GPS :

$$\Pr(\lambda_{ij}^* \leq RR_0)$$

$$= w_{ij} F_{\mathbf{Ga}}(RR_0; \hat{\alpha}_1 + n_{ij}, \hat{\beta}_1 + e_{ij}) + (1 - w_{ij}) F_{\mathbf{Ga}}(RR_0; \hat{\alpha}_2 + n_{ij}, \hat{\beta}_2 + e_{ij})$$

- BCPNN :

$$\Pr(IC_{ij}^* \leq \log_2(RR_0))$$

No analytic form  $\rightarrow$  Monte Carlo simulations

## Bayesian methods : Proposed approach (3)

### Decision rule $d_{ij}$

#### ► GPS

DuMouchel (1999) :  $d_{ij} = \mathbf{1}[\mathbf{E}\{\log_2(\lambda_{ij}^*)\} > \tau]$

DuMouchel *et al.* (2001) :  $d_{ij} = \mathbf{1}[\mathbf{Q}_{0.05}(\lambda_{ij}^*) > \tau]$

Our suggestion :  $d_{ij} = \mathbf{1}[u_{ij} \leq \alpha]$

Szarfman *et al.* (2002) :  $\text{RR}_0 = 2$  and  $\alpha = 0.05$

#### ► BCPNN

Our suggestion :  $d_{ij} = \mathbf{1}[u_{ij} \leq \alpha]$

Bate *et al.* (1998) :  $\text{RR}_0 = 1$  and  $\alpha = 0.025$

Description of the current methods

Extension to the multiple comparison setting

**Simulation study**

Application to the French pharmacovigilance data

Discussion

# Simulation study

## Objectives

- ▶ To compare the performances of the methods
- ▶ To evaluate the quality of the FDR estimators

## Methods

- ▶ Frequentist methods :
  - ROR « new »
  - RFET
  - midRFET
- ▶ Bayesian methods :
  - GPS :  $E\{\log_2(\lambda_{ij}^*)\}$ ,  $Q_{0.05}(\lambda_{ij}^*)$ ,  $\Pr(H_{0ij}^*)$
  - BCPNN :  $\Pr(H_{0ij}^*)$
- ▶ 3 different tested hypotheses based on  $\{\psi_0, RR_0\} = 1, 2$  and 5

## Simulation study

### Data generation


- ▶ Model :  $\mathbf{n}_{ij} \sim \text{Mu}(n, \mathbf{p}_{ij})$  from the French database
  - ▶  $\mathbf{p}_{ij}$ 
    - $\mathbf{p}_{i.}^w \sim \text{Di}(\mathbf{n}_{i.})$
    - $\mathbf{p}_{.j}^w \sim \text{Di}(\mathbf{n}_{.j})$
    - $\log(r_{ij}^w) \sim \text{Lo}(0, 0.5)$
- $$\implies p_{ij} = \frac{r_{ij}^w p_{i.}^w p_{.j}^w}{\sum_{ij} r_{ij}^w p_{i.}^w p_{.j}^w}$$
- ▶ From  $\mathbf{p}_{ij}$ 
    - $n_{ij}$ s and the true marginal probabilities :  $p_{i.} = \sum_j p_{ij}$      $p_{.j} = \sum_i p_{ij}$
    - real status of the cells according to
      - $\psi_{ij}$ , and  $\psi_0$  for the frequentist methods
      - $\text{RR}_{ij} = \frac{p_{ij}}{p_{i.} p_{.j}}$  and  $\text{RR}_0$  for the bayesian methods

### Simulation plan

- ▶ 500 simulated datasets
- ▶ « True » FDR estimated by the average of the FDPs over the 500 datasets
- ▶  $n_{ij} \geq 3$


# Simulation study : Comparison of the frequentist methods

## FDR



# Simulation study : Comparison of the frequentist methods


## FDR and estimation





## Simulation study : Comparison of the Bayesian methods (1)


### GPS and decision rules



- ▶ The proposed decision rule gives better results according to the FDR
- ▶ Close performances between  $Q_{0.05}(\lambda_{ij}^*)$  and  $\Pr(H_{0ij}^*)$  for small values of FDR

# GPS vs BCPNN with $\Pr(H_{0ij}^*)$


## FDR and estimation



- ▶ Very close performances according to the FDR


# GPS vs BCPNN with $\Pr(H_{0ij}^*)$

## FDR and estimation




- ▶ Very close performances according to the FDR
- ▶ Large differences in the FDR estimation

## Global Comparison



- ▶ Very close performances according to the FDR
- ▶ Large differences in FDR estimation

## Global Comparison



- ▶ Very close performances according to the FDR
- ▶ Large differences in FDR estimation

Results in favor of the use of the GPS model with  $\Pr(H_{0ij}^*)$

Description of the current methods

Extension to the multiple comparison setting

Simulation study


**Application to the French pharmacovigilance data**

Discussion

## Global analysis (1)

- ▶ 1984-2003
- ▶  $n_{ij} \geq 3 \rightarrow 47\,520$  cells

### FDR estimation



- ▶ Results close to that obtained in the simulation study

## Feasibility Study

Afssaps is interested in implementing an automatic signal detection tool in France

### Objective

A feasibility study was recently conducted with two aims

- ▶ Relevance of the signals generated by the method
- ▶ Time necessary for the evaluation of the signals



# Feasibility Study

## Methodology

- ▶ Use of  $GPS_{pH0}$  with FDR at 5%
- ▶ A first analysis was performed on the data (Jan 1 2000 - dec 31 2008)
- ▶ A second analysis was performed three months later (Jan 1 2000 - March 31 2009)
- ▶ Selection of the 1414 signals that were highlighted by the second analysis but not by the first one
- ▶ These signals were dispatched among the 31 regional pharmacovigilance centres and the pharmacovigilance department at Afssaps (about 40 signals per centre)

# Feasibility Study

## Methodology

The centres were given one month to

- ▶ categorize the signals
  - known/nothing further
  - known/further follow up
  - unknown/further follow up
  - unknown/outlier
  - no time to assess
  
- ▶ Evaluate the time necessary for the analysis

# Feasibility Study

## Results

- ▶ 28 centres participated (sent back the questionnaire)  $\implies$  1294 signals
- ▶ 1170 signals were categorised
  - 35.7% known/nothing further
  - 6.9% known/further follow up
  - 16.8% unknown/further follow up
  - 36.6% unknown/outlier
  - 4% no time to assess
- ▶ Large variability in the time necessary for analysis
  - between 2 and 26 hours per centre
  - median : 6 hours

## Conclusion

- ▶ 277 signal worth following up
- ▶ At least 60% of relevant signals
- ▶ The lack of precision was often invoked for the outliers : too vague signals  
 $\implies$  need to work out the coding dictionaries

Description of the current methods

Extension to the multiple comparison setting

Simulation study

Application to the French pharmacovigilance data

Discussion

## Discussion (1)

### Extension of the existing methods to the multiple comparison framework

- ▶ No modification of the model
- ▶ New decision rules

The GPS model with  $\Pr(H_{0_{ij}}^*)$  provides the best results

- ▶ in the simulation study
- ▶ in the sequential evaluation study

## Discussion (2)

### Limits of the GPS model

- ▶ Data represented as a contingency table
  - Common to all the methods currently used
  - co-prescription

### Use of penalized regressions

- ▶ Logistic regression in which
  - One studies one adverse event at a time
  - Several hundred of predictors : the drugs (coded in 1/0)
  - Several hundred thousand (or millions) of individuals
- ▶ Lasso type algorithm / Stability Selection (Meinshausen & Bühlmann JRSS B 2010)
- ▶ Much more intensive
- ▶ Should make it possible to better account for the correlation structure between the drugs
  - co-prescription
- ▶ Direct extension to the study of the interaction drug-drug

## References



I Ahmed, C Dalmaso, F Haramburu, F Thiessard, P Broët, and P Tubert-Bitter.

False discovery rate estimation for frequentist pharmacovigilance signal detection methods.

*Biometrics*, 66(1) :301–309, March 2010.

PMID : 19432790.



I Ahmed, F Thiessard, G Miremont-Salamé, B Bégaud, and P Tubert-Bitter.

Pharmacovigilance data mining with methods based on false discovery rates : a comparative simulation study.

*Clinical Pharmacology and Therapeutics*, 88(4) :492–498, October 2010.

PMID : 20811349.



Ismail Ahmed, Françoise Haramburu, Annie Fourier-Réglat, Frantz Thiessard, Carmen Kreft-Jais, Ghada Miremont-Salamé, Bernard Bégaud, and Pascale Tubert-Bitter.

Bayesian pharmacovigilance signal detection methods revisited in a multiple comparison setting.

*Statistics in Medicine*, 28(13) :1774–1792, June 2009.

PMID : 19360795.